Zoledronic acid increases disease-free survival in premenopausal women with HR+ early

[News]

Adjuvant treatment with the bone sparing drug zoledronic acid plus hormonal therapy with the aromatase inhibitor letrozole significantly increases disease-free survival compared to tamoxifen in premenopausal women with hormone receptor positive (HR+) early breast cancer, according to results reported at ESMO 2018 Congress in Munich.

More... (https://www.news-medical.net/news/20181022/Zoledronic-acid-increases-disease-free-survival-in-premenopausal-women-with-HR2b-early-breast-cancer.aspx)